Spotlight on Cancer Moonshot 2020

Cancer Moonshot 2020 plans to break down barriers and enable progress by enhancing data access,…


OncoSec Summer Wrap-Up and Future Outlook

As the summer comes to an end, school begins, and the cool weather starts to set in, we wanted to…


President Jimmy Carter to Undergo Immunotherapy Treatment

News of the United States’ 39th President Jimmy Carter and his recent diagnosis of advanced…


First Patient Enrolled in Combination Study with UCSF and Merck

On behalf of the OncoSec team, we’re thrilled to announce the first patient enrolled in the Phase…


OncoSec Rings Nasdaq Opening Bell

We were thrilled to participate in the Nasdaq Opening Bell Ceremony to celebrate our recent listing…


ASCO 2015 Round-Up: Immunotherapy in the Spotlight

As June marks Cancer Immunotherapy Awareness Month, I wanted to reflect on some of the key…


Upward and Onwards: OncoSec Moves to The NASDAQ Capital Market

On May 27th, we proudly announced that our common stock has been listed on The NASDAQ Capital…


Innovation Through An Academic Network: Part 3 The Future of Pharma

Looking ahead, our work is cut out for us in terms of R&D as many diseases and conditions are…